Tenaya Therapeutics Files 2025 Proxy Statement
Ticker: TNYA · Form: DEF 14A · Filed: Apr 17, 2025
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Tenaya's proxy statement is out for the May 28th meeting - vote your shares!
AI Summary
Tenaya Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 17, 2025, for its annual meeting on May 28, 2025. The company, focused on biological products, is seeking shareholder approval for matters related to its corporate governance and operations. The filing details executive compensation, board nominations, and other shareholder proposals.
Why It Matters
This filing provides shareholders with crucial information to make informed decisions regarding the company's leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing, providing information to shareholders for an upcoming meeting, and does not inherently present new financial risks.
Key Numbers
- 20250528 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250417 — Filing Date (The proxy statement was officially filed with the SEC on this date.)
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- 0001193125-25-084313 (filing_id) — Accession Number
- 20250417 (date) — Filing Date
- 20250528 (date) — Meeting Date
- 171 Oyster Point Blvd., Suite 500 (address) — Company Headquarters
- South San Francisco, CA 94080 (address) — Company Headquarters
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information and solicit their votes for the annual meeting of shareholders scheduled for May 28, 2025.
When is the annual meeting of Tenaya Therapeutics, Inc. shareholders scheduled?
The annual meeting is scheduled for May 28, 2025.
What is the filing date of this definitive proxy statement?
The definitive proxy statement was filed on April 17, 2025.
Where is Tenaya Therapeutics, Inc. headquartered?
Tenaya Therapeutics, Inc. is headquartered at 171 Oyster Point Blvd., Suite 500, South San Francisco, CA 94080.
What is the SIC code for Tenaya Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Tenaya Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 17, 2025 regarding Tenaya Therapeutics, Inc. (TNYA).